Clinical Trials Directory

Trials / Completed

CompletedNCT03869476

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.

Pilot Study for the Development of a Non-invasive Diagnostic Score to Differentiate Between Essential Thrombocythemia, Premyelofibrosis and Myelofibrosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
133 (actual)
Sponsor
University Hospital, Angers · Other Government
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.

Detailed description

The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia (TE) and overt myelofibrosis (or primary myelofibrosis): prefibrotic myelofibrosis. Prefibrotic myelofibrosis patients seem to have a poorer prognosis compared to essential thrombocythemia in term of overall survival and myelofibrotic evolution. The dichotomy between these diseases is based on the bone marrow biopsy evaluation and is challenging with a lack of reproducibility showed in the literature. This study aims to develop a diagnostic non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis. The parameters studied are : * spleen fibrosis by elastography * plasma cytokines levels * mutationnal landscape by NGS * CD34 circulating cells Bone marrow biopsy were reviewed by 2 anatomopathologists. Number of patients to be enrolled : 130

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTNon-invasive diagnosis score* spleen fibrosis by elastography * plasma cytokines levels * mutationnal landscape by NGS * CD34 circulating cells

Timeline

Start date
2019-07-30
Primary completion
2024-01-30
Completion
2024-01-30
First posted
2019-03-11
Last updated
2024-12-30

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03869476. Inclusion in this directory is not an endorsement.